Ipamorelin vs Hexarelin: Selective vs Non-Selective GHRP

Hexarelin (hexarelin acetate) and ipamorelin are both synthetic GHRPs that activate the GHS-R1a (ghrelin receptor) to stimulate GH release from pituitary somatotrophs. Both produce potent GH pulses and meaningful IGF-1 elevation. However, their hormonal selectivity profiles are fundamentally different.

Hexarelin is a first-generation GHRP with strong GH-releasing potency but poor receptor selectivity. It activates GHS-R1a broadly across pituitary cell types, and its structure leads to significant cross-activation of ACTH-releasing corticotrophs and prolactin-secreting lactotrophs. Arvat et al. (1997, PMID 9285939) documented that hexarelin at 1 mcg/kg IV raises cortisol by 50 to 80% above baseline within 30 minutes. Prolactin elevation is similarly documented.

Ipamorelin is a second-generation GHRP specifically engineered for somatotroph selectivity. Raun et al. (1998, PMID 9849822) confirmed that ipamorelin produces potent GH release without significant ACTH, cortisol, or prolactin elevation at doses up to 200 times the effective GH-releasing dose. This selectivity fundamentally changes the risk profile.

For bodybuilders, cortisol is a catabolic hormone that opposes the anabolic environment GH peptide protocols are designed to support. Using hexarelin means accepting a simultaneous cortisol elevation that directly counteracts part of the GH benefit. Ipamorelin avoids this self-defeating dynamic.

GHS-R1a receptor selectivity:

• Ipamorelin: highly selective for somatotrophs (GH-releasing cells); minimal activation of corticotrophs, lactotrophs, or hypothalamic neurons
• Hexarelin: non-selective GHS-R1a activation; stimulates somatotrophs, corticotrophs, lactotrophs, and hypothalamic neurons producing the ACTH, cortisol, and prolactin side effects

Cortisol effect:

• Ipamorelin: no significant cortisol elevation at any dose tested, including 200x the effective GH dose (Raun 1998, PMID 9849822)
• Hexarelin: cortisol rises 50 to 80% above baseline within 30 minutes of a 1 mcg/kg IV dose (Arvat 1997, PMID 9285939); significant in absolute terms

ACTH effect:

• Ipamorelin: no significant ACTH change (Raun 1998)
• Hexarelin: ACTH rises proportionally with cortisol; the ACTH rise precedes and drives the cortisol elevation

Prolactin effect:

• Ipamorelin: no significant prolactin elevation (Raun 1998)
• Hexarelin: elevates prolactin through lactotroph GHS-R1a activation; magnitude varies by dose and individual

GH release potency:

• At equivalent doses, hexarelin may produce slightly higher peak GH due to its less restricted mechanism; however, the collateral hormonal side effects make dose-for-dose comparison less clinically relevant
• Ipamorelin at standard doses (200 to 300 mcg SC) produces clinically meaningful GH pulses and IGF-1 elevation of 15 to 40% above baseline

Receptor downregulation and desensitisation:

• Hexarelin: documented GHS-R1a downregulation with repeated dosing; chronic use attenuates the GH response
• Ipamorelin: some receptor accommodation with continuous daily use, but the desensitisation is generally less pronounced than with non-selective GHRPs; pulsatile injection protocols (rather than continuous infusion) help preserve receptor sensitivity

Cardiovascular effects:

• Hexarelin has documented cardioprotective properties through GHS-R1a activation in cardiac tissue, which was studied as a potential heart failure treatment (Muccioli et al., 2004). This is a GHRP class effect that ipamorelin likely shares but is less studied for.

GH pulse synergy with GHRH analogs:

• Both ipamorelin and hexarelin synergise with GHRH analogs (CJC-1295 no-DAC, tesamorelin) to produce larger GH pulses
• The CJC-1295 no-DAC plus ipamorelin stack is the standard because it adds GHRH priming to ipamorelin's selective GH trigger without adding cortisol or prolactin load
• CJC-1295 no-DAC plus hexarelin would produce larger GH pulses but with significant cortisol and prolactin elevation from the hexarelin component

Choose ipamorelin if:

• You want GH and IGF-1 elevation without cortisol or prolactin side effects
• You are managing a stack with AAS that already carry cortisol-relevant risks (trenbolone has MR agonism; high-dose testosterone affects SHBG dynamics)
• You are gynecomastia-prone and want to minimise prolactin exposure
• You are in a cutting phase where cortisol elevation would impair muscle preservation and sleep quality
• You want a compound you can pair cleanly with CJC-1295 no-DAC without hormonal complications from the GHRP component
• Long-term continuous use is planned; ipamorelin's selectivity makes year-round use more sustainable

Choose hexarelin only if:

• You specifically want the GH pulse amplitude of a non-selective GHRP and have managed the cortisol and prolactin side effects with cabergoline and cortisol-control supplements
• You are using it for cardiac research or injury recovery contexts where GHS-R1a cardiac action is specifically targeted
• You have physician supervision and are monitoring ACTH, cortisol, and prolactin carefully

In practice: Hexarelin has been largely displaced by ipamorelin in bodybuilding use precisely because ipamorelin provides equivalent or superior GH elevation per unit of hormonal disruption. There is no scenario where hexarelin is clearly superior for a bodybuilder's purposes, given ipamorelin's equivalent GH efficacy with a dramatically cleaner hormonal profile.